Dual GIP/GLP-1 agonist
A dual GIP/GLP-1 receptor agonist used in metabolic and weight management contexts.
Supported by large randomised trials in diabetes and weight management. As with semaglutide, that evidence is for the registered, brand-name product.
Gastrointestinal side effects are common and prescribers screen for contraindications. Unapproved or compounded copies fall outside that oversight.
A registered prescription medicine in Australia for defined indications. Supply is via prescription and dispensing pharmacy.
Lawful access is via prescription and pharmacy dispensing of the registered product, subject to availability.
Semaglutide targets the GLP-1 receptor; tirzepatide targets both GIP and GLP-1 receptors. Both are registered prescription medicines for defined indications.
This entry is general information about Tirzepatide, not a recommendation to use it. We don’t provide dosing, protocols or sourcing. Speak to a registered practitioner.
This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.